RELATED REPORTS
Tags: adverse eventsalyconebendamustinebloodblood cancerbortezomibcancercross trial comparisoncyclophosphamidedexamethasoneelderlygerigeriatrichematologyhemeinductionixazomibmaintenancemaintenance therapyMMmultiple myelomaneuropathynewly diagnosed multiple myelomaoncologyorroverall response rateperipheral neuropathypfspnprogression-free survivalsurvivalthalidomidetolerabilitytransplant ineligibletreatment discontinuationvistawell-tolerated